2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Study Population, Human, Animal Model
PAPER

686 Implantable black phosphorus chips enable sustained and controllable in vivo CAR-T cell generation for multiple myeloma therapy

Shijing Wang, PhD, Bin Sun, MD2, Sandhya Rai3, Xinyi Yang, PhD4, Tyce Kearl, MD, PhD5, Jing Dong, PhD6, Peiman Hematti, MD7, Siegfried Janz, MD8, Binod Dhakal, MD, MS9, Joseph Zenga, MD, MS10, Yujun Zhang, PhD11, Fumou Sun, PhD12
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, North Dakota State University, Fargo, North Dakota, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
12 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction: BCMA CAR T-cell (CART) therapy has produced deep and durable responses in multiple myeloma (MM). However, its widespread use remains limited by complex, costly ex vivo manufacturing that requires leukapheresis, genetic modification, prolonged cell expansion, and centralized quality testing. Direct generation of CARTs in vivo could eliminate many of these barriers. Still, intravenous lipid nanoparticle (LNP) approaches are limited by rapid systemic clearance, off-target uptake, brief interaction with circulating T cells, and low CART yield. To overcome these limitations, we developed an implantable, biodegradable black phosphorus chip (BChip) serving as a localized in vivo CART factory. The multilayer scaffold provides sustained local cargo delivery: CXCL9 recruits T cells, surface-bound anti-CD3 captures and activates them, and BCMA CAR-encoding circular RNA (circRNA)-loaded LNPs induce CAR expression. Newly generated CARTs subsequently enter the circulation to eliminate MM, while the intrinsic photothermal properties of black phosphorus enable near-infrared (NIR)-triggered termination of further CART generation.

Methods: Black phosphorus crystals were liquid-exfoliated into nanosheets, coated with poly-L-lysine, and assembled into multilayer BChips. Surface amines were activated using EDC/NHS chemistry before sequential incorporation of CXCL9, anti-CD3 antibodies, and BCMA CAR circRNA-loaded LNPs. Scaffold morphology was characterized by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Cy7-labeled BChips or luciferase-circRNA-loaded BChips were implanted subcutaneously in BALB/c mice to evaluate implant retention, biodegradation, reporter expression, T-cell recruitment, hematologic parameters, and major organ histopathology. Antitumor efficacy was evaluated in NSG mice bearing disseminated luciferase-expressing OPM2 myeloma after intravenous infusion of human peripheral blood mononuclear cells. Mice received either subcutaneous BCMA-CAR@LNP-loaded BChips or matched BCMA-CAR@LNPs intravenously. CART generation, systemic trafficking, and tumor burden were assessed by fluorescence imaging, flow cytometry, and bioluminescence imaging. To evaluate controlled inactivation, implanted BChips were exposed to an 808-nm laser, and residual transfection activity was measured.

Results: TEM and AFM confirmed successful assembly of multilayer BChips, converting thin black phosphorus nanosheets (<50 nm) into scaffolds approximately 5 μm in diameter and 500 nm thick. Following subcutaneous implantation, BChips remained localized, gradually degraded over time, and were detectable for up to 28 days, demonstrating prolonged local retention. No significant hematologic abnormalities or major-organ toxicity were observed. CXCL9 functionalization markedly enhanced local T-cell recruitment, with DiR-labeled T cells accumulating within 24 hours and persisting for at least 14 days. Consistent with prolonged T-cell recruitment and sustained vector exposure, CXCL9/anti-CD3-functionalized BChips carrying luciferase circRNA-loaded LNPs generated stronger and longer-lasting reporter expression than control BChips, maintaining circRNA-mediated expression for up to 21 days.

In the disseminated OPM2 model, approximately 15% of circulating mononuclear cells expressed BCMA CAR by day 5 following BChip implantation, resulting in effective suppression of tumor burden within 28 days. In contrast, intravenously administered BCMA-CAR@LNPs produced substantially weaker antitumor activity, highlighting the advantages of localized and sustained in vivo T-cell engineering. Finally, NIR irradiation heated the BChip to 47°C and reduced subsequent reporter transfection by more than 95%, demonstrating effective termination of additional CART generation.

Conclusions: The biodegradable BChip addresses major limitations of systemic in vivo CART delivery by integrating sustained local vector release, active T-cell recruitment, and controllable circRNA-mediated CAR expression within a single implantable platform. This strategy generated functional BCMA CARTs in vivo, produced superior antimyeloma activity compared with intravenous LNP delivery, and enabled NIR-triggered termination of further CART production. These findings establish an implantable, controllable platform for simplified in vivo CART manufacturing and support its further development as a clinically translatable alternative to conventional ex vivo CART production for MM.

Shijing Wang, PhD: No relevant conflicts of interest to declare.